Inxight Drugs

WAY 267464 dihydrochloride is a potent and selective agonist at the oxytocin receptor (OTR). WAY 267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin. WAY 267464 dose-dependently reduced anxiety on the four-plate test and prevented the deficits in prepulse inhibition induced by MK-801 or amphetamine. The ability of WAY 267464 to function as a V1AR antagonist may limit its potential therapeutic use in humans, as it would conceivably prevent the improvements in social behavior and social cognition that may be assumed to arise from a primary OTR agonist action.

ALTERNATIVE DEFINITION for [Oxytocin]

MORE DETAILS

1JQS135EYN

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

ALTERNATIVE DEFINITION for [OXYTOCIN CITRATE]

MORE DETAILS

1573L6WJ8U

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

ALTERNATIVE DEFINITION for [OXYTOCIN ACETATE]

MORE DETAILS

4NR672T8NL

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

ATOSIBAN ACETATE

MORE DETAILS

0P5DNO7CEF

Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Conditions:

Atosiban (brand name Tractocile) is a competitive antagonist of human oxytocin at receptor level. In rats and guinea pigs, atosiban was shown to bind to oxytocin receptors, to decrease the frequency of contractions and the tone of the uterine musculature, resulting in a suppression of uterine contractions. Atosiban was also shown to bind to the vasopressin receptor, thus inhibiting the effect of vasopressin. Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: − regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes − a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% − a gestational age from 24 until 33 completed weeks − a normal foetal heart rate. Atosiban does not have U.S. Food and Drug Administration (FDA) approval for use in the United States.